Vericel (VCEL) Return on Capital Employed (2011 - 2026)
Vericel's (VCEL) quarterly Return on Capital Employed came in at 3.59% in Q1 2026, up 431.0% year-on-year from 0.68% in Q1 2025, and up 36.91% quarter-over-quarter from 2.62% in Q4 2025.
Vericel (VCEL) Return on Capital Employed (2011 - 2026) Analysis & Trends
Vericel has disclosed Return on Capital Employed across 16 years of filings, most recently posting 3.59% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 3.59%, up 431.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 3.59% (up 431.0% YoY), and the FY2025 annual result was 2.69%, up 137.0% from the prior year.
- Return on Capital Employed came in at 3.59% for Q1 2026 at Vericel, up from 2.62% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 3.59% in Q1 2026 to a low of 8.66% in Q3 2022.
- The 5-year median for Return on Capital Employed is 1.18% (2024), against an average of 2.57%.
- Across the five-year window, Return on Capital Employed sank 1244 bps in 2022 and soared 630 bps in 2024, its largest moves.
- Vericel's Return on Capital Employed stood at 7.65% in 2022, then soared by 71 bps to 2.23% in 2023, then jumped by 156 bps to 1.25% in 2024, then jumped by 109 bps to 2.62% in 2025, then jumped by 37 bps to 3.59% in 2026.
- The last three Return on Capital Employed figures came in at 3.59% (Q1 2026), 2.62% (Q4 2025), and 1.78% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | 3.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.59% |
| Dec 31, 2025 | 2.62% |
| Sep 30, 2025 | 1.78% |
| Jun 30, 2025 | 0.31% |
| Mar 31, 2025 | -0.72% |
| Dec 31, 2024 | 1.25% |
| Sep 30, 2024 | -0.36% |
| Jun 30, 2024 | -1.18% |
| Mar 31, 2024 | -1.18% |
| Dec 31, 2023 | -2.23% |
| Sep 30, 2023 | -4.71% |
| Jun 30, 2023 | -5.88% |
| Mar 31, 2023 | -7.47% |
| Dec 31, 2022 | -7.65% |
| Sep 30, 2022 | -8.66% |
| Jun 30, 2022 | -7.90% |
| Mar 31, 2022 | -5.37% |
| Dec 31, 2021 | -3.78% |
| Sep 30, 2021 | 0.14% |
| Jun 30, 2021 | 4.55% |